ProPhase Labs, Inc. Amortization of Intangible Assets
ProPhase Labs, Inc. (PRPH) reported Amortization of Intangible Assets of $600.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-19
- ProPhase Labs, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $600.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $700.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $600.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. amortization of intangible assets for fiscal 2025 was $2.60M, a 0.00% change from fiscal 2024.
- ProPhase Labs, Inc. amortization of intangible assets for fiscal 2024 was $2.60M, a 10.34% decline from fiscal 2023.
- ProPhase Labs, Inc. amortization of intangible assets for fiscal 2023 was $2.90M, a 20.83% increase from fiscal 2022.
- ProPhase Labs, Inc. amortization of intangible assets for fiscal 2022 was $2.40M, a 71.43% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $600.00K 10-Q · filed 2026-08-19 | $1.30M derived: sum of 3 quarters · filed 2026-08-19 | $1.90M derived: sum of 4 quarters · filed 2026-08-19 | |||
| 2026-03-31 | $600.00K 10-Q/A · filed 2026-07-09 | $1.30M derived: sum of 2 quarters · filed 2026-07-09 | $1.90M derived: sum of 3 quarters · filed 2026-07-09 | $2.50M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2025-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.30M derived: sum of 2 quarters · filed 2026-06-01 | $1.90M derived: sum of 3 quarters · filed 2026-06-01 | $2.60M 10-K · filed 2026-06-01 | |||
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-19 | $1.20M derived: sum of 2 quarters · filed 2025-11-19 | $1.90M 10-Q · filed 2025-11-19 | $2.50M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2025-06-30 | $600.00K 10-Q · filed 2025-08-13 | $600.00K 10-Q · filed 2026-08-19 | $1.30M 10-Q · filed 2025-08-13 | $1.90M derived: sum of 3 quarters · filed 2026-07-09 | $2.50M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2025-03-31 | $600.00K 10-Q/A · filed 2026-07-09 | $1.30M derived: sum of 2 quarters · filed 2026-07-09 | $1.90M derived: sum of 3 quarters · filed 2026-07-09 | $2.50M derived: sum of 4 quarters · filed 2026-07-09 | |||
| 2024-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.30M derived: sum of 2 quarters · filed 2026-06-01 | $1.90M derived: sum of 3 quarters · filed 2026-06-01 | $2.60M 10-K · filed 2026-06-01 | |||
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-19 | $1.20M derived: sum of 2 quarters · filed 2025-11-19 | $1.90M 10-Q · filed 2025-11-19 | $2.40M derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-13 | $1.30M 10-Q · filed 2025-08-13 | $1.80M derived: sum of 3 quarters · filed 2025-08-13 | $2.60M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-20 | $646.00K 10-Q · filed 2024-05-10 | $1.20M derived: sum of 2 quarters · filed 2025-05-20 | $2.00M derived: sum of 3 quarters · filed 2025-05-20 | $2.80M derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $1.40M derived: sum of 2 quarters · filed 2025-04-01 | $2.20M derived: sum of 3 quarters · filed 2025-04-01 | $2.90M 10-K · filed 2025-04-01 | |||
| 2023-09-30 | $800.00K 10-Q · filed 2024-11-13 | $1.60M derived: sum of 2 quarters · filed 2024-11-13 | $2.30M 10-Q · filed 2024-11-13 | $2.75M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-14 | $1.50M 10-Q · filed 2024-08-14 | $1.95M derived: sum of 3 quarters · filed 2024-08-14 | $2.45M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $754.00K 10-Q · filed 2024-05-10 | $1.15M derived: sum of 2 quarters · filed 2024-05-10 | $1.65M derived: sum of 3 quarters · filed 2024-05-10 | $2.35M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $900.00K derived: sum of 2 quarters · filed 2024-03-29 | $1.60M derived: sum of 3 quarters · filed 2024-03-29 | $2.40M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-13 | $545.00K 10-Q · filed 2022-11-10 | $1.20M derived: sum of 2 quarters · filed 2023-11-13 | $2.00M 10-Q · filed 2023-11-13 | $2.65M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $700.00K 10-Q · filed 2023-08-11 | $709.00K 10-Q · filed 2022-08-12 | $1.40M 10-Q · filed 2023-08-11 | $2.15M derived: sum of 3 quarters · filed 2023-08-11 | $2.59M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $709.00K 10-Q · filed 2023-05-12 | $1.45M derived: sum of 2 quarters · filed 2023-05-12 | $1.89M derived: sum of 3 quarters · filed 2023-05-12 | $2.00M derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.18M derived: sum of 2 quarters · filed 2023-03-29 | $1.29M derived: sum of 3 quarters · filed 2023-03-29 | $1.40M 10-K · filed 2023-03-29 | $1.37M 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $445.00K 10-Q · filed 2022-11-10 | $554.00K derived: sum of 2 quarters · filed 2022-11-10 | $662.00K 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $109.00K 10-Q · filed 2022-08-12 | $207.00M 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | $109.00K 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | $73.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |